Young Research-Driven Startup Brings Clinical-Grade Cognitive Risk Assessment to Home Settings, Eliminating Cost and Access Barriers
AlziDetect, a healthcare technology startup founded by passionate neurobiologist Ryan Zhu, has announced the launch of its pioneering camera-based screening platform designed to identify early-stage cognitive decline associated with Alzheimer’s disease. The technology marks a significant shift in how families and healthcare providers can approach early detection, removing critical barriers of cost, accessibility, and wait times that have long delayed diagnosis.
Currently, individuals concerned about cognitive decline face a lengthy diagnostic pathway. Specialist referrals, multi-month waiting lists, and expensive imaging procedures costing thousands of dollars create a bottleneck that can delay intervention by years. AlziDetect’s solution changes this equation entirely.
How It Works
The platform utilizes advanced facial recognition technology to analyze 468 unique facial landmarks, focusing specifically on eye-face coupling patterns supported by peer-reviewed neuroscience research. A standard laptop camera conducts the screening in under three minutes, with users receiving clinically-informed results directly at home. The approach requires no specialist involvement, medical facility access, or expensive equipment, making comprehensive cognitive health screening genuinely accessible for the first time.
“We’re bridging a massive gap between what research has proven possible and what patients can actually access,” said Ryan Zhu, Founder and Neuro Lead of AlziDetect. “As a neurobiologist, I’ve seen firsthand how early intervention in cognitive decline can make a profound difference in quality of life and disease progression. Our mission is to ensure that financial constraints or geographical limitations never prevent families from getting answers when they need them most.”
Rigorous Scientific Foundation
AlziDetect is not operating in isolation. The methodology is grounded in published peer-reviewed research and complemented by ongoing clinical validation studies. The team is currently conducting research accepted to IEEE COMPSAC in collaboration with The Hong Kong Polytechnic University and The Education University of Hong Kong, while simultaneously partnering with established clinical and hospital networks to validate results against clinical standards.
The work has already garnered recognition from leading innovation programs, including selection as a Blue Ocean Top 100 company, a Conrad Challenge Silver award, and recognition as a Diamond Challenge Semi-Finalist.
Building the Full Ecosystem
Screening represents only the entry point. AlziDetect is developing a comprehensive platform that includes clinician-guided education to help users understand results, progress monitoring capabilities to track cognitive changes over time, and family-centered memory preservation tools.
A Young Team Driving Innovation
What sets AlziDetect apart is the depth of expertise combined with the drive and perspective of its founding team. Technical Lead Ali-Mansur Valiyev is engineering the healthcare economics and accessibility frameworks that make the screening paradigm viable, while directly overseeing the technical architecture of the platform and leading portions of the IEEE COMPSAC research initiative. Ryan Zhu, drawing on his background in neurobiology and entrepreneurship, is driving the neuroscience foundation of the screening approach and shaping the clinical validation strategy.
Head of Outreach Kubby Bhatia is actively bridging the gap between the technology and the communities it serves, leveraging expertise in AI, entrepreneurship, and economics to ensure equitable access and drive adoption. Eklavya Tomar, working as an AI and Health Integrated Engineer, is building the core technical solutions at the intersection of artificial intelligence and clinical healthcare requirements. Neil Sharma, contributing as a Healthcare AI Programmer, is actively developing the technology infrastructure that powers the platform.
Together, this young team is addressing one of healthcare’s most pressing challenges: turning laboratory-proven science into real-world solutions that save lives.
What’s Next
AlziDetect is currently in the clinical validation phase, working intensively with healthcare partners to ensure the technology meets rigorous scientific standards before wider deployment. The company is actively seeking partnerships with clinicians, researchers, and healthcare systems interested in participating in validation studies.
For more information, visit alzidetect.com.
About AlziDetect
AlziDetect is a healthcare technology startup developing accessible, camera-based screening tools for early Alzheimer’s risk detection. Founded by a team of passionate researchers and entrepreneurs, the company aims to eliminate barriers to early cognitive assessment and enable earlier intervention for cognitive decline.
